Recent projections could create an environment of unprecedented demand for nuclear imaging.
Bayer’s latest contrast agent is proving its potential in clinical trials as a promising alternative to agents with higher gadolinium content.
New survey data indicate that addressing the effect of technologists’ missed opportunities during their training may be a yearslong effort.